Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trospium chloride/xanomeline - Karuna Therapeutics

Next Previous
Drug Profile

Trospium chloride/xanomeline - Karuna Therapeutics

Alternative Names: BMS-986510; COBENFY; Karuna-Xanomeline-Trospium - Karuna Therapeutics; KarXT - Karuna Therapeutics; Trospium chloride/LY-246708 - Karuna Therapeutics; Trospium chloride/xanomeline tartrate - Karuna Therapeutics; Xanomeline tartrate/ trospium chloride - Karuna Therapeutics; Xanomeline/trospium chloride - Karuna Therapeutics

Latest Information Update: 30 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PureTech Health
  • Developer Karuna Therapeutics; ZAI Lab
  • Class Analgesics; Antidementias; Antipsychotics; Antispasmodics; Benzhydryl compounds; Benzilates; Esters; Nortropanes; Pyridines; Small molecules; Spiro compounds; Thiadiazoles; Urologics
  • Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Schizophrenia
  • Phase III Bipolar disorders; Psychotic disorders
  • Discontinued Pain

Most Recent Events

  • 11 Jun 2025 Phase-III clinical trials in Bipolar disorders in USA (unspecified route) (NCT06951698)
  • 10 Jun 2025 Phase-III clinical trials in Schizophrenia in Japan (PO) (NCT06882785)
  • 10 Jun 2025 Bristol-Myers Squibb plans a phase III ADAGIO-2 trial for Alzheimer disease (Combination therapy) in Argentina, Chile, Czechia, France, Germany, Hungary, Israel, Italy, South Korea, Poland, Puerto Rico, UK and the US (PO) in July 2025 (NCT07011745)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top